Ipsen S.A. reports 1H results, FY25 guidance
Source: SeekingAlpha
2025-07-31 13:24:58 ET
More on Ipsen S.A.
- Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors
- Madrigal, Ipsen, SpringWorks get EU backing for their drugs
- Historical earnings data for Ipsen S.A.
- Dividend scorecard for Ipsen S.A.
- Financial information for Ipsen S.A.
Read the full article on Seeking Alpha
For further details see:
Ipsen S.A. reports 1H results, FY25 guidance
Ipsen
NASDAQ: IPSEF
IPSEF Trading
100.0% G/L:
$113.13 Last:
5 Volume:
$0 Open:
IPSEF Latest News
March 09, 2026 02:00:00 am
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
